Welcome!

News Feed Item

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014

NEW YORK, April 24, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014

http://www.reportlinker.com/p02063647/Gastroesophageal-GE-Junction-Carcinomas-Global-Clinical-Trials-Review-H1-2014.html

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014" provides data on the Gastroesophageal (GE) Junction Carcinomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastroesophageal (GE) Junction Carcinomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gastroesophageal (GE) Junction Carcinomas. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Introduction 7
Gastroesophageal (GE) Junction Carcinomas 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Unaccomplished Trials of Gastroesophageal (GE) Junction Carcinomas 26
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials 32
Prominent Drugs 34
Latest Clinical Trials News on Gastroesophageal (GE) Junction Carcinomas 35
May 16, 2012: Amgen Presents Results From Exploratory Biomarker Analysis Of Rilotumumab 35
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
AstraZeneca PLC 36
Clinical Trial Overview of AstraZeneca PLC 36
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
Amgen Inc. 38
Clinical Trial Overview of Amgen Inc. 38
Novartis AG 39
Clinical Trial Overview of Novartis AG 39
Bristol-Myers Squibb Company 40
Clinical Trial Overview of Bristol-Myers Squibb Company 40
Eli Lilly and Company 41
Clinical Trial Overview of Eli Lilly and Company 41
C. H. Boehringer Sohn AG & Co. KG 42
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 42
Dainippon Sumitomo Pharma Co., Ltd. 43
Clinical Trial Overview of Dainippon Sumitomo Pharma Co., Ltd. 43
Aphton Corporation (Inactive) 44
Clinical Trial Overview of Aphton Corporation (Inactive) 44
Amgen research GmbH 45
Clinical Trial Overview of Amgen research GmbH 45
Clinical Trial Overview of Top Institutes / Government 46
National Cancer Institute 46
Clinical Trial Overview of National Cancer Institute 46
North Central Cancer Treatment Group 48
Clinical Trial Overview of North Central Cancer Treatment Group 48
Case Comprehensive Cancer Center 49
Clinical Trial Overview of Case Comprehensive Cancer Center 49
Stanford University 50
Clinical Trial Overview of Stanford University 50
Sidney Kimmel Comprehensive Cancer Center 51
Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center 51
Memorial Sloan Kettering Cancer Center 52
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 52
Southwest Oncology Group 53
Clinical Trial Overview of Southwest Oncology Group 53
University of Pittsburgh 54
Clinical Trial Overview of University of Pittsburgh 54
Fox Chase Cancer Center 55
Clinical Trial Overview of Fox Chase Cancer Center 55
The University of Texas M. D. Anderson Cancer Center 56
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 56
Five Key Clinical Profiles 57
Appendix 104
Abbreviations 104
Definitions 104
Research Methodology 105
Secondary Research 105
About GlobalData 106
Contact Us 106
Disclaimer 106
Source 107

List of Tables

Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Region, 2014* 8
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 11
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 15
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Phase, 2014* 22
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 23
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Suspended Clinical Trials, 2014* 26
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Gastroesophageal (GE) Junction Carcinomas Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 30
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 36
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 37
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 38
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 39
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 40
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 41
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 42
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Dainippon Sumitomo Pharma Co., Ltd., 2014* 43
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Aphton Corporation (Inactive), 2014* 44
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen research GmbH, 2014* 45
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 46
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by North Central Cancer Treatment Group, 2014* 48
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 49
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 50
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2014* 51
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 52
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 53
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 54
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Fox Chase Cancer Center, 2014* 55
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 56

List of Figures
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 11
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 15
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Phase (%), 2014* 22
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 23
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Gastroesophageal (GE) Junction Carcinomas Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 30
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
GlobalData Methodology 105

To order this report: Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02063647/Gastroesophageal-GE-Junction-Carcinomas-Global-Clinical-Trials-Review-H1-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abil...
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
With over 720 million Internet users and 40–50% CAGR, the Chinese Cloud Computing market has been booming. When talking about cloud computing, what are the Chinese users of cloud thinking about? What is the most powerful force that can push them to make the buying decision? How to tap into them? In his session at 18th Cloud Expo, Yu Hao, CEO and co-founder of SpeedyCloud, answered these questions and discussed the results of SpeedyCloud’s survey.
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Actian Corporation has announced the latest version of the Actian Vector in Hadoop (VectorH) database, generally available at the end of July. VectorH is based on the same query engine that powers Actian Vector, which recently doubled the TPC-H benchmark record for non-clustered systems at the 3000GB scale factor (see tpc.org/3323). The ability to easily ingest information from different data sources and rapidly develop queries to make better business decisions is becoming increasingly importan...
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
As the world moves toward more DevOps and Microservices, application deployment to the cloud ought to become a lot simpler. The Microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a complete developer-oriented Platform as a Service (PaaS) that is IaaS agnostic and supports vCloud, OpenStack and AWS. Serverless computing is revolutionizing computing. In his session at 19th Cloud Expo, Raghav...
SYS-CON Events announced today Telecom Reseller has been named “Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...